Ablynx is looking for new partners to take its rheumatoid arthritis drug vobarilizumab into phase 3 development, after AbbVie turned down an option to license the drug. AbbVie has already paid the ...
Sanofi has leapt in to buy Ablynx for €3.9 billion ($4.85bn) outbidding an offer from Novo Nordisk which the European biotech had declined two weeks ago. For Sanofi, the acquisition comes hot on ...
Round co-led by BGF, Octopus Ventures and M Ventures, with support from new corporate investor, Eli Lilly and Company, and ...
MoonLake Immunotherapeutics to host a Capital Markets Updateon Wednesday, September 11 ZUG, Switzerland, September 9, 2024 – ...
MoonLake Immunotherapeutics to host a Capital Markets Updateon Wednesday, September 11 ZUG, Switzerland, September 9, 2024 - MoonLake Immunotherapeutics AG ("MoonLake"; Nasdaq: MLTX), a clinical-stage ...
NanoSyrinx, the synthetic biology company developing ‘nanosyringes’ as a novel platform for targeted intracellular delivery ...
Objectives This study aimed to evaluate the long-term safety and efficacy profiles of ozoralizumab in patients with rheumatoid arthritis (RA) from the OHZORA, NATSUZORA and HOSHIZORA trials. Methods ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback